Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2026 Mar 24;17:1784546. doi: 10.3389/fimmu.2026.1784546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2026 Iacovelli, Sanjabi, Monemi, Amitai, Decalf, Moussion, Liao, Rao, Getz and Mancuso.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Panel A shows a line chart of mean ± SD pharmacokinetic (PK) concentrations over time for five single ascending dose groups, with concentrations increasing by dose. Panel B shows a line chart of mean ± SD PK concentrations for two multiple ascending dose groups, with both groups demonstrating decreased concentrations over time following repeated dosing. Both panels use a logarithmic y-axis labeled with ug/mL and report small sample sizes per group. — Serum concentration-time profiles of RO7497987 in (A) SAD and (B) MAD cohorts. One participant in SAD Cohort 5 was removed as samples were missing due to early termination. MAD cohorts (7 mg and 21 mg) received 2 doses of RO7497987 at the specified dose level 21 days apart by IV infusion. The black dashed line represents the lower limit of quantification (0.00313 ug/mL).